Overview
Levisonics is building a platform called acoustic tweezing rheometry to analyze liquids non-contactly from a small sample (a drop of blood). The system measures how a sample coagulates, polymerizes, or flows (rheology) by applying acoustic forces to the drop and observing its deformation, enabling fast, safe, and comprehensive assessment of bleeding and thrombotic risks in neonatal, pediatric, and adult patients. It can also function as real-time quality control for food, liquids, and gels during manufacturing. Compared with competitors, Levisonics emphasizes non-contact measurement, very small sample volumes, and the ability to deliver rapid results for both clinical risk assessment and manufacturing QC. The company’s goal is to provide a practical, non-invasive tool for predicting bleeding/thrombosis risk and ensuring product quality in real time across medical and industrial settings.
Work here?Claim your company
Simplify's take
What believers are saying
- NIH awarded $299,000 on May 23, 2024, extending hemophilia development.
- DoD granted $4.3 million on March 15, 2024 for trauma coagulometry.
- Levisonics posted five active jobs in 2026, signaling ongoing technical hiring.
What critics are saying
- No commercial revenue exists yet, leaving grants as the only financing engine.
- Headcount fell from nine employees in 2025 to five in June 2026.
- Abbott, Siemens, Werfen, and HemoSonics can outspend and out-distribute before 2027.
What makes Levisonics unique
- Levisonics's acoustic tweezing spectroscopy analyzes 4–6 microliters non-contactly, unlike benchtop coagulation analyzers.
- Tulane, Indiana University, and NHLBI-backed studies validate trauma and hemophilia workflows.
- Five employees in 2026 keep the company focused on one platform.
Help us improve and share your feedback! Did you find this helpful?